Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells

BACKGROUND: Breast cancer is one the highest causes of female cancer death worldwide. Many standard chemotherapeutic agents currently used to treat breast cancer are relatively non-specific and act on all rapidly dividing cells. In recent years, more specific targeted therapies have been introduced....

Descripción completa

Detalles Bibliográficos
Autores principales: Rashid-Kolvear, Fariborz, Taboski, Michael AS, Nguyen, Johnny, Wang, Dong-Yu, Harrington, Lea A, Done, Susan J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915983/
https://www.ncbi.nlm.nih.gov/pubmed/20650001
http://dx.doi.org/10.1186/1471-2407-10-390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915983/
https://www.ncbi.nlm.nih.gov/pubmed/20650001
http://dx.doi.org/10.1186/1471-2407-10-390

Ejemplares similares